Clinical Trials in North Carolina

Showing 9761-9780 of 15,496 trials

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

NCT03900676

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose-ranging Study in the Treatment of Acne Vulgaris,

Acne Vulgaris

Vyome Therapeutics Inc.480 participantsStarted Apr 2019

Ontario, California, United States • Sherman Oaks, California, United States • Brandon, Florida, United States +9 more locations

COMPLETEDPhase 238 miles

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01666444

The purpose of this study is to compare the overall survival of patients treated with VTX-2337 + pegylated liposomal doxorubicin (PLD) versus those treated with PLD alone in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer. VTX-2337, a small molecule agonist of Toll-like Receptor 8 (TLR8), activates multiple components of the innate immune system and is being developed as a novel therapeutic agent for use in oncology. Experimental data obtained in an animal model of ovarian cancer supports the combination of VTX-2337 with PLD. In this model, the combination of VTX-2337 and PLD resulted in a significant reduction in tumor growth compared to either agent alone and an increase in the number of T lymphocytes infiltrating the tumor. The combination of PLD and VTX-2337 has been tested in a small number of women with ovarian cancer in a Phase 1b study and appears to be generally well-tolerated.

Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Celgene297 participantsStarted Oct 2012

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Burbank, California, United States +133 more locations

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Find Trials by Condition in North Carolina

A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Contrast-enhanced Ultrasound of the Kidney

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

A Study in Advanced Solid Tumors

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

Building an Optimal Hand Hygiene Bundle

Study of Ramucirumab in Ovarian Cancer

Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia

Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma